Women's ProblemsDiabetes & EndocrinologyFamily PracticeNursingOBGYN & Women's HealthHematology & OncologyConditionsInfertilityWomen HealthWomen'S Health
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Oct. 26, 2017 (HealthDay News) -- The demand for fertility preservation is increasing, and methods to address it include oocyte cryopreservation and ovarian-tissue cryopreservation, according to a review article published online Oct. 25 in the New England Journal of Medicine.
Jacques Donnez, M.D., Ph.D., and Marie-Madeleine Dolmans, M.D., Ph.D., from the Université Catholique de Louvain in Belgium, discussed methods for fertility preservation in women.
Indications for fertility preservation include malignant disease, particularly hematologic cancers and breast cancer; benign conditions including autoimmune and hematologic conditions as well as endometriosis and ovarian torsion; and age-related fertility decline. The researchers note that oocyte cryopreservation by vitrification provides the highest yield and is suitable for women with benign diseases, those seeking fertility preservation for personal reasons, and women with cancer if treatment can be delayed. Embryo cryopreservation requires a male partner or use of a donor sperm; cryopreservation of mature oocytes can circumvent some related ethical and legal concerns. For adolescents and women in whom cancer treatment cannot be postponed, ovarian-tissue cryopreservation is specifically indicated; however, this technique is still considered experimental.
"Improving freezing techniques, ensuring safe ovarian-tissue transportation (to provide and extend access to fertility preservation in large countries and low-resource areas), and minimizing the risks of fertility-preservation strategies in patients with cancer constitute formidable challenges for the coming decade," the authors write.
One author disclosed ties to Gedeon Richter.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 29, 2022
Read this Next
Other Trending Articles